| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Mellen Center for Multiple Sclerosis Treatment and Research, Departments of Neurology (Drs. Rudick and Miller) and Biomedical Engineering (Dr. Fisher), Cleveland Clinic Foundation, OH; Center for Research Methodology and Biometrics (Dr. Cutter and M. Baier), AMC Cancer Center, Lakewood, CO; Department of Neurology (Dr. Dougherty), Walter Reed Army Medical Center, Washington, DC; Department of Neurology (Dr. Weinstock–Guttman), Buffalo General Hospital, NY; Department of Neurology (Dr. Mass), Oregon Health Sciences Center, Portland; and Biogen, Inc. (Dr. Simonian), Cambridge, MA.
Address correspondence and reprint requests to Dr. Richard A. Rudick, Mellen Center, Area U100, Cleveland Clinic Foundation 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: rudickr{at}ccf.org
OBJECTIVE: To determine whether the MS Functional Composite (MSFC) can predict future disease progression in patients with relapsing remitting MS (RR-MS).
BACKGROUND: The MSFC was recommended by the Clinical Outcomes Assessment Task Force of the National MS Society as a new clinical outcome measure for clinical trials. The MSFC, which contains a test of walking speed, arm dexterity, and cognitive function, is expressed as a single score on a continuous scale. It was thought to offer improved reliability and responsiveness compared with traditional clinical MS outcome measures. The predictive value of MSFC scores in RR-MS has not been determined.
METHODS: The authors conducted a follow-up study of patients with RR-MS who participated in a phase III study of interferon ß-1a (AVONEX) to determine the predictive value of MSFC scores. MSFC scores were constructed from data obtained during the phase III trial. Patients were evaluated by neurologic and MRI examinations after an average interval of 8.1 years from the start of the clinical trial. The relationships between MSFC scores during the clinical trial and follow-up status were determined.
RESULTS: MSFC scores from the phase III clinical trial strongly predicted clinical and MRI status at the follow-up visit. Baseline MSFC scores, and change in MSFC score over 2 years correlated with both disability status and the severity of whole brain atrophy at follow-up. There were also significant correlations between MSFC scores during the clinical trial and patient-reported quality of life at follow-up. The correlation with whole brain atrophy at follow-up was stronger for baseline MSFC than for baseline EDSS.
CONCLUSION: MSFC scores in patients with RR-MS predict the level of disability and extent of brain atrophy 6 to 8 years later. MSFC scores may prove useful to assign prognosis, monitor patients during early stages of MS, and to assess treatment effects.
This article has been cited by other articles:
|
|
 |
|
  E. D Festa, K. Hankiewicz, S. Kim, J. Skurnick, L. J Wolansky, S. D Cook, and D. Cadavid Serum levels of CXCL13 are elevated in active multiple sclerosis Multiple Sclerosis, November 1, 2009; 15(11): 1271 - 1279. [Abstract] [PDF]
|
|
|
|
|
|
L Strober, J Englert, F Munschauer, B Weinstock-Guttman, S Rao, and R. Benedict Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS Multiple Sclerosis, September 1, 2009; 15(9): 1077 - 1084. [Abstract] [PDF]
|
|
|
|
|
|
R. Rudick, C. Polman, J. Cohen, M. Walton, A. Miller, C Confavreux, F. Lublin, M Hutchinson, P. O'Connor, S. Schwid, et al. Assessing disability progression with the Multiple Sclerosis Functional Composite Multiple Sclerosis, August 1, 2009; 15(8): 984 - 997. [Abstract] [PDF]
|
|
|
|
|
|
B Brochet, M. Deloire, M Bonnet, E Salort-Campana, J. Ouallet, K. Petry, and V Dousset Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study Multiple Sclerosis, November 1, 2008; 14(9): 1242 - 1249. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Schmitz-Hubsch, P. Giunti, D. A. Stephenson, C. Globas, L. Baliko, F. Sacca, C. Mariotti, M. Rakowicz, S. Szymanski, J. Infante, et al. SCA Functional Index: A useful compound performance measure for spinocerebellar ataxia Neurology, August 12, 2008; 71(7): 486 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Kragt, A. J. Thompson, X. Montalban, M. Tintore, J. Rio, C. H. Polman, and B.M.J. Uitdehaag Responsiveness and predictive value of EDSS and MSFC in primary progressive MS Neurology, March 25, 2008; 70(13_Part_2): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ehrenreich, B. Fischer, C. Norra, F. Schellenberger, N. Stender, M. Stiefel, A.-L. Siren, W. Paulus, K.-A. Nave, R. Gold, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis Brain, October 1, 2007; 130(10): 2577 - 2588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Younes, J. Hill, J. Quinless, M. Kilduff, B. Peng, S. Cook, and D. Cadavid Internet-based cognitive testing in multiple sclerosis Multiple Sclerosis, September 1, 2007; 13(8): 1011 - 1019. [Abstract] [PDF]
|
|
|
|
|
|
O. Khan Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology, May 29, 2007; 68(22_suppl_3): S64 - S71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Solaro, G. Brichetto, M. Casadio, L. Roccatagliata, P. Ruggiu, G.L. Mancardi, P.G. Morasso, P. Tanganelli, and V. Sanguineti Subtle upper limb impairment in asymptomatic multiple sclerosis subjects Multiple Sclerosis, April 1, 2007; 13(3): 428 - 432. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Langer-Gould, R. A. Popat, S. M. Huang, K. Cobb, P. Fontoura, M. K. Gould, and L. M. Nelson Clinical and Demographic Predictors of Long-term Disability in Patients With Relapsing-Remitting Multiple Sclerosis: A Systematic Review Arch Neurol, December 1, 2006; 63(12): 1686 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M M Nieuwenhuis, H Van Tongeren, P S Sorensen, and M Ravnborg The Six Spot Step Test: a new measurement for walking ability in multiple sclerosis Multiple Sclerosis, August 1, 2006; 12(4): 495 - 500. [Abstract] [PDF]
|
|
|
|
|
|
D M Miller, J A Cohen, M Kooijmans, E Tsao, G Cutter, M Baier, and IMPACT Investigators Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study Multiple Sclerosis, April 1, 2006; 12(2): 180 - 186. [Abstract] [PDF]
|
|
|
|
|
|
R A Rudick, G R Cutter, M Baier, B Weinstock-Guttman, M K Mass, E Fisher, D M Miller, and A W Sandrock Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients Multiple Sclerosis, December 1, 2005; 11(6): 626 - 634. [Abstract] [PDF]
|
|
|
|
|
|
G. P.A. Rice, H.-P. Hartung, and P. A. Calabresi Anti-{alpha}4 integrin therapy for multiple sclerosis: Mechanisms and rationale Neurology, April 26, 2005; 64(8): 1336 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Ravnborg, M Blinkenberg, F Sellebjerg, M Ballegaard, S H. Larsen, and P S. Sorensen Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale Multiple Sclerosis, February 1, 2005; 11(1): 81 - 84. [Abstract] [PDF]
|
|
|
|
|
|
S. A. Rizvi and M. A. Agius Current approved options for treating patients with multiple sclerosis Neurology, December 28, 2004; 63(12_suppl_6): S8 - S14. [Abstract] [Full Text]
|
|
|
|
|
|
J Hobart, N Kalkers, F Barkhof, B Uitdehaag, C Polman, and A Thompson Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional C omposite Multiple Sclerosis, February 1, 2004; 10(1): 41 - 46. [Abstract] [PDF]
|
|
|
|
|
|
B Weinstock-Guttman, M Baier, R Stockton, A Weinstock, T Justinger, F Munschauer, C Brownscheidle, J Williams, E Fisher, D Miller, et al. Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis Multiple Sclerosis, October 1, 2003; 9(5): 529 - 534. [Abstract] [PDF]
|
|
|
|
|
|
M. Rovaris, F. Agosta, M. P. Sormani, M. Inglese, V. Martinelli, G. Comi, and M. Filippi Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study Brain, October 1, 2003; 126(10): 2323 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M Miller, R. A Rudick, M. Baier, G. Cutter, D. S Doughtery, B. Weinstock-Guttman, M. K Mass, E. Fisher, and N. Simonian Factors that predict Health-Related Q uality of Life in patients with relapsing -remitting multiple sclerosis Multiple Sclerosis, February 1, 2003; 9(1): 1 - 5. [Abstract] [PDF]
|
|
|
|
|
|
M W Nortvedt and T Riise The use of quality of life measures in multiple sclerosis research Multiple Sclerosis, February 1, 2003; 9(1): 63 - 72. [Abstract] [PDF]
|
|
|
|
|
|
E. Fisher, R. A. Rudick, J. H. Simon, G. Cutter, M. Baier, J. -C. Lee, D. Miller, B. Weinstock-Guttman, M. K. Mass, D. S. Dougherty, et al. Eight-year follow-up study of brain atrophy in patients with MS Neurology, November 12, 2002; 59(9): 1412 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R A Rudick, G Cutter, and S Reingold The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials Multiple Sclerosis, October 1, 2002; 8(5): 359 - 365. [Abstract] [PDF]
|
|
|
|
|
|
N. F. Kalkers, N. Ameziane, J. C. J. Bot, A. Minneboo, C. H. Polman, and F. Barkhof Longitudinal Brain Volume Measurement in Multiple Sclerosis: Rate of Brain Atrophy Is Independent of the Disease Subtype Arch Neurol, October 1, 2002; 59(10): 1572 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cohen, G. R. Cutter, J. S. Fischer, A. D. Goodman, F. R. Heidenreich, M. F. Kooijmans, A. W. Sandrock, R. A. Rudick, J. H. Simon, N. A. Simonian, et al. Benefit of interferon {beta}-1a on MSFC progression in secondary progressive MS Neurology, September 10, 2002; 59(5): 679 - 687. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
